Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Blood pressure drug may boost liver cancer treatment power

NCT ID NCT07302919

Summary

This study is testing whether adding a common blood pressure medication (nicardipine) to a standard liver cancer treatment makes it work better. The standard treatment, called TACE, involves injecting tiny beads loaded with chemotherapy directly into the liver tumor. Researchers think the blood pressure drug might help stop the tumor from resisting the chemotherapy, leading to more complete tumor death. The study will involve about 152 adults with a specific type of liver cancer who cannot have surgery.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATO CELLULAR CARCINOMA (HCC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hôpitaux Universitaires de Genève

    RECRUITING

    Geneva, 1205, Switzerland

    Contact

    Contact

  • Kantonsspital St. Gallen

    RECRUITING

    Sankt Gallen, 9007, Switzerland

    Contact

    Contact

  • University Hospital Basel

    RECRUITING

    Basel, 4031, Switzerland

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.